Carbogen Amcis teams with liposomal delivery tech firm for HP API biz

By Gareth Macdonald

- Last updated on GMT

Related tags: Active ingredient, Pharmacology

Carbogen Amcis has signed a strategic deal with formulations specialist Polymun Scientific in a agreement designed to support the development of its high potency manufacturing business.

The deal – terms of which were not disclosed – will grant Carbogen access to Austria-based Polymun’s liposomal formulation technology for use in the formulations of active pharmaceutical ingredients (APIs).

In return Polymun will be able to use Carbogen’s development and manufacturing capabilities.

Carbogen CEO Mark Griffiths set out the rationale for the agreement, explaining that: “We believe that our customers are interested in finding new ways to better deliver highly potent active ingredients. This alliance expands our portfolio of offering and moves us one step closer to achieving this goal​.”

The Switzerland-based API maker has been expanding its high-potency API manufacturing business since February this year under a restructuring plan launched​ by Indian parent organisation Dishman in response to ‘inadequate profitability’ at the Swiss CMO.

Under that plan the active pharmaceutical ingredient (API) chose to focus operations at its Aarau, Switzerland on development projects and shift pilot production for early-stage compounds to its facility in Huzenschwil.

Large volume production for standard APIs and highly active agents continued at Carbogen's facility in Bubendorf.

There was more news for Carbogen’s HPAPI business this month process after the firm successfully completed​ a US Food and Drug Administration (FDA) pre-approval inspection for the manufacture of a HP API on behalf of an unnamed multinational pharmaceutical organisation.

Carbogen was unable to provide further information on the specifics of the agreement ahead of publication.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more